Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Gains from Investment Securities: 2011-2025

Historic Gains from Investment Securities for Anika Therapeutics (ANIK) over the last 10 years, with Sep 2025 value amounting to $13,000.

  • Anika Therapeutics' Gains from Investment Securities fell 40.91% to $13,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 113.97%. This contributed to the annual value of $2.1 million for FY2024, which is 15.24% up from last year.
  • Per Anika Therapeutics' latest filing, its Gains from Investment Securities stood at $13,000 for Q3 2025, which was down 84.15% from $82,000 recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Gains from Investment Securities ranged from a high of $2.2 million in Q1 2024 and a low of -$13.7 million during Q2 2021.
  • In the last 3 years, Anika Therapeutics' Gains from Investment Securities had a median value of $429,000 in 2023 and averaged $791,858.
  • Within the past 5 years, the most significant YoY rise in Anika Therapeutics' Gains from Investment Securities was 132.03% (2022), while the steepest drop was 1,391.52% (2022).
  • Quarterly analysis of 5 years shows Anika Therapeutics' Gains from Investment Securities stood at $825,000 in 2021, then tumbled by 1,391.52% to -$10.7 million in 2022, then spiked by 110.14% to $1.1 million in 2023, then spiked by 36.11% to $1.5 million in 2024, then plummeted by 40.91% to $13,000 in 2025.
  • Its Gains from Investment Securities stands at $13,000 for Q3 2025, versus $82,000 for Q2 2025 and $1.5 million for Q1 2025.